In ALK F1174L and F1245C-mutant cell lines and patient-derived xenografts, whereas treatment with either agent alone delayed tumour growth, the combination of ceritinib and ribociclib led to a complete and sustained tumour regression [97]. This evidence concerns the gene ALK and neoplasm.